Carnegie Investment Counsel Grows Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Carnegie Investment Counsel grew its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 22.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 460,274 shares of the company's stock after buying an additional 83,364 shares during the quarter. Carnegie Investment Counsel owned 0.21% of Hims & Hers Health worth $12,782,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the company. UMB Bank n.a. lifted its holdings in shares of Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after buying an additional 933 shares during the period. Larson Financial Group LLC raised its position in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after acquiring an additional 458 shares in the last quarter. Tsfg LLC acquired a new stake in Hims & Hers Health in the first quarter valued at $46,000. Fifth Third Bancorp boosted its position in shares of Hims & Hers Health by 165.4% during the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after purchasing an additional 961 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth $38,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of research analyst reports. Piper Sandler reiterated a "neutral" rating and issued a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Truist Financial boosted their price target on Hims & Hers Health from $45.00 to $48.00 and gave the stock a "hold" rating in a research note on Thursday, July 17th. Finally, Morgan Stanley restated an "equal weight" rating and issued a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health presently has an average rating of "Hold" and an average price target of $39.83.

Hims & Hers Health Trading Up 0.3%

Shares of Hims & Hers Health stock traded up $0.18 during mid-day trading on Friday, hitting $57.50. 46,302,225 shares of the stock were exchanged, compared to its average volume of 30,801,588. The stock has a market capitalization of $12.87 billion, a price-to-earnings ratio of 83.33, a price-to-earnings-growth ratio of 2.11 and a beta of 2.02. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The company has a 50-day simple moving average of $53.15 and a 200 day simple moving average of $42.77.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The business's revenue was up 110.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.05 earnings per share. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Michael Chi sold 17,102 shares of the firm's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total value of $1,021,844.50. Following the transaction, the insider directly owned 278,654 shares in the company, valued at $16,649,576.50. This trade represents a 5.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $58.40, for a total value of $7,482,616.80. Following the completion of the transaction, the chief executive officer directly owned 89,311 shares in the company, valued at $5,215,762.40. This represents a 58.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 788,368 shares of company stock valued at $42,410,254 in the last 90 days. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.